PhD Student in Cancer Research - JP0618

To be part of the Tumor Stroma Interactions research group (Head: PI: Dr. E. Moussay and Dr. Jérôme Paggetti) within the Laboratory of Experimental Cancer Research of LIH.
84, rue Val Fleuri, Luxembourg L-1526, Luxembourg
16/07/2018 12:19:01

Chronic Lymphocytic Leukemia (CLL) represents the most frequent leukemia in adults. Despite recent advances in treatments, CLL remains a deadly uncurable disease. This cancer is caracterized by an accumulation of abnormal, apoptosis resistant, B lymphocytes in the blood and lymphoid organs of the patients. CLL progression is highly dependent on complex interactions between tumor cells and their microenvironment. Indeed, CLL cells can modify stromal cells and immune cells to promote their survival and to escape from the immune surveillance system.


Our team focuses on the mechanisms leading to leukemia progression, in particular the influence of CLL cells on stromal cells and immune cells located in their microenvironment, with the goal to identify new prognostic markers and therapeutic targets.

Training and research environment

Tumor Stroma Interactions research group is a dynamic and multinational team whose current members originate from France, Belgium, Germany and Italy. It belongs to the Department of Oncology, whose research activities focus on the cellular and molecular mechanisms of tumor progression using a wide range of cutting edge technologies, including genomic, transcriptomic and proteomic analyses, as well as in vitro and in vivo imaging modalities using state-of-the art animal models for cancer research. PhD student will be in charge of a TELEVIE funded project that aims to explore the interplay between tumor cells and regulatory T cells, and will be co-supervised by Dr. E. Moussay (PI), Dr. J. Paggetti (PI).

Recent related reference (open access): Paggetti J, et al. Exosomes released by chronic lymphocytic leukemia cells induce cancer-associated fibroblast formation. Blood 126(9):1106-17.
Wierz M,et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood 131(14):1617-1621. (IF:13.164)


·         Master’s degree in Biomedical Sciences or Immunology. Prior experience in cancer research would be an advantage, but is not mandatory.

·         Experience in cell culture, PCR, Western-Blot and flow-cytometry techniques.

·         Mouse  experimentation practice and FELASA (or equivalent) diploma would be considered as an asset.

·         Excellent time management, rigor, perseverance, scientific creativity and originality, writing skills,  sense of priority and ability to work with others.

·         Fluency in English is mandatory.

2 year fixed-term contract (renewable for 2 years), full time. Start-date: October 2018


More information about the group can be found here :

Scientific contact: Dr. Jérôme Paggetti, PhD

Tel : 00352 26 970 340 or

Researchers are supported by easy access to scientific expertise, well-equipped facilities, an active seminar program as well as the possibility for close collaborations with universities and other research institutes.